Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Long-Term Investments: 2020-2024

Historic Long-Term Investments for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $657.0 million.

  • Relay Therapeutics' Long-Term Investments fell 26.54% to $504.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $504.9 million, marking a year-over-year decrease of 26.54%. This contributed to the annual value of $657.0 million for FY2024, which is 8.36% up from last year.
  • According to the latest figures from FY2024, Relay Therapeutics' Long-Term Investments is $657.0 million, which was up 8.36% from $606.4 million recorded in FY2023.
  • Relay Therapeutics' 5-year Long-Term Investments high stood at $847.1 million for FY2022, and its period low was $230.4 million during FY2020.
  • Over the past 3 years, Relay Therapeutics' median Long-Term Investments value was $657.0 million (recorded in 2024), while the average stood at $703.5 million.
  • As far as peak fluctuations go, Relay Therapeutics' Long-Term Investments soared by 194.23% in 2021, and later fell by 28.42% in 2023.
  • Yearly analysis of 5 years shows Relay Therapeutics' Long-Term Investments stood at $230.4 million in 2020, then surged by 194.23% to $678.0 million in 2021, then rose by 24.95% to $847.1 million in 2022, then decreased by 28.42% to $606.4 million in 2023, then increased by 8.36% to $657.0 million in 2024.